GLP-1 for Weight Loss Without Diabetes: What the 2026 Systematic Review Found
You don't need to have diabetes to benefit from GLP-1 therapy. A comprehensive 2026 systematic review confirms what the peptide community has known for years — and the results are striking.
You don't need to have diabetes to benefit from GLP-1 therapy. A comprehensive 2026 systematic review confirms what the peptide community has known for years — and the results are striking.
Peptide South Africa Research Research TeamEditorial
#GLP-1#2026#obesity#weight loss#semaglutide#metabolic health#non-diabetic#retatrutide#fat-loss#systematic review#tirzepatide#peptidesShare this articleTwitterLinkedInTrack Your Peptide Protocols
Use Peptide South Africa Research to log injections, calculate doses, access our peptide library, and optimize your protocols.
Download Peptide South Africa ResearchExplore More Peptide ResourcesFree peptide calculators·Peptide research hub·Peptide glossary·Semaglutide guide·BPC-157 guide·Best peptide calculator
More in Research
SLU-PP-332: The ERRα Agonist That Gives You the Benefits of Exercise in a Vial
SLU-PP-332 is a small-molecule ERRα agonist with remarkable endurance, fat oxidation, and mitochondrial benefits. Here's the complete guide to what it does, who it's for, and how to use it.
Selank and Semax: The Complete Protocol for Calm Focus and Cognitive Enhancement
Selank and Semax are two of the most powerful intranasal nootropic peptides available. Here's how they work, how they differ, and the best protocols for using them separately or stacked.
GHK-Cu and Cognitive Aging: New Research on the Copper Peptide's Brain Benefits
GHK-Cu and Cognitive Aging: New Research on the Copper Peptide's Brain Benefits A 2026 preprint shows GHK-Cu reverses markers of cognitive aging in mouse models. Here's what the science says and what it means for your stack.